Trials Sponsors Conditions Drugs Pricing

Conditions

Genomic Instability Prognostic Cancer Model

Outcome Measures

Primary Outcomes (1)

Overall survival
5 year overall survival
5 year

Study Arms (2)

Successful Conversion Therapy Group (SCTG)

All cases were categorized into a successful conversion therapy group

Failed Conversion Therapy Group (FCTG)

if they achieved no evidence of disease (NED) status through surgery after conversion therapy, and a failed conversion therapy group

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

In this study, after excluding patients who could not complete the entire treatment regimen or did not meet the inclusion criteria, a total of 286 patients were initially diagnosed with colorectal cancer with synchronous liver metastasis, all with an initial treatment goal of No Evidence of Disease (NED). Preoperative conversion therapy was administered based on NGS results. Eventually, 106 patients achieved successful conversion (SCTG) and underwent resection or ablation of the primary and metastatic lesions, attaining NED status. Meanwhile, 180 patients, after first-line treatment, were confirmed by MDT to have unresectable metastases and were classified as the Failed Conversion Therapy Group (FCTG).

You may qualify if:

Sponsors & Collaborators

The First Affiliated Hospital with Nanjing Medical University
Otherlead

Biospecimen

Retention: SAMPLES WITH DNA

Formalin-fixed paraffin-embedded (FFPE) tumor samples were procured via colonoscopic biopsies.

MeSH Terms

Conditions

Genomic Instability

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Yueming Sun, Ph.D.;M.D.
The First Affiliated Hospital with Nanjing Medical University
PRINCIPAL INVESTIGATOR

Enrollment

286 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Dr. Yueming Sun

Study Record Dates

First Submitted

June 22, 2024

First Posted

June 27, 2024

Study Start

January 1, 2016

Actual (reported)

Genomic Signatures for Patients With Initially Unresectable Colorectal Liver Metastases

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Successful Conversion Therapy Group (SCTG)

Failed Conversion Therapy Group (FCTG)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Successful Conversion Therapy Group (SCTG)

Failed Conversion Therapy Group (FCTG)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record